Is Blackrock Going "Activist" With AstraZeneca?

Mark Melin

Published onMay 22, 2014

Updated on May 13, 2021

Is the activist strategy spreading to traditional establishment investors such as BlackRock, Inc. (NYSE:BLK)?

Table of Contents

Blackrock communicating its desires to AstraZeneca

BlackRock, Inc. (NYSE:BLK), the epitome of establishment institutional investing, may be finding its voice. The New York Times is reporting that BlackRock, AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN)’s largest shareholder, is making public its desire for the drug maker to renew talks with Pfizer Inc. (NYSE:PFE) about a potential deal.

Typically conservative institutional investors seldom, if ever, speak against management decisions in the companies in which they were invested. BlackRock, Inc. (NYSE:BLK)’s, which is an 8% owner in AstraZeneca plc (ADR)...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Is Blackrock Going "Activist" With AstraZeneca?

Blackrock communicating its desires to AstraZeneca

Login required to continue reading.

Get Your Business News